Clinical Trials Logo

Herpes Zoster clinical trials

View clinical trials related to Herpes Zoster.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05966090 Active, not recruiting - Clinical trials for Respiratory Syncytial Virus Infections

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

RSV-OA=ADJ-020
Start date: July 28, 2023
Phase: Phase 3
Study type: Interventional

To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged >=50 years of age.

NCT ID: NCT05871541 Active, not recruiting - Infectious Disease Clinical Trials

A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

JCXH-105
Start date: May 26, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to assess the safety and immunogenicity of a self-replicating (sr) RNA-based vaccine, JCXH-105, in the prevention of Shingles (Herpes Zoster) Participant will be randomized to receive either JCXH-105 or Shingrix.

NCT ID: NCT05856084 Active, not recruiting - Herpes Zoster Clinical Trials

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Start date: May 7, 2023
Phase: Phase 2
Study type: Interventional

The purposes of the study are to evaluate the immunogenicity and safety of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 30 years and older.

NCT ID: NCT05839301 Active, not recruiting - Varicella Clinical Trials

A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

Start date: April 27, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to evaluate the lot-to-lot consistency, immunogenicity, and safety of live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.

NCT ID: NCT05701800 Active, not recruiting - Herpes Zoster Clinical Trials

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

Start date: January 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this first-in-human study is to generate sufficient safety and immunogenicity data to enable the selection of an appropriate dose level for the initiation of a Phase 2/3 study.

NCT ID: NCT05669625 Active, not recruiting - Varicella Clinical Trials

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine

Start date: December 26, 2022
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.

NCT ID: NCT05636436 Active, not recruiting - Herpes Zoster Clinical Trials

Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

Start date: December 7, 2022
Phase: Phase 1
Study type: Interventional

The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to preliminarily explore immunogenicity.

NCT ID: NCT05470855 Active, not recruiting - Varicella Clinical Trials

Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province

Start date: July 6, 2022
Phase: Phase 4
Study type: Interventional

This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the protective effect of varicella vaccine in children aged 1-12 years and the correlation between varicella antibody and protective effect,to evaluate the immunogenicity and safety of varicella vaccine in children aged 1-12 years.

NCT ID: NCT05371080 Active, not recruiting - Herpes Zoster Clinical Trials

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Start date: August 10, 2022
Phase: Phase 3
Study type: Interventional

The purpose of the current ZOSTER-101 long-term follow-up (LTFU) study of ZOSTER-049 (NCT02723773) study, an extension of ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies, is to assess the long-term vaccine efficacy (VE) against Herpes Zoster (HZ) (approximately 11-15 years post primary vaccination in ZOSTER-006/022 studies), persistence of immunogenicity and safety of GSK's Herpes Zoster subunit (HZ/su) vaccine in older adults. The persistence of immunogenicity and safety of 1 or 2 additional doses (0, 2-month schedule) of HZ/su vaccine administered to a small group of participants in ZOSTER-049 study (approximately 5 years after the initial vaccination in ZOSTER-006/022 studies) will also be assessed.

NCT ID: NCT05304351 Active, not recruiting - Herpes Zoster Clinical Trials

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

Start date: February 2, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and immunogenicity of CRV-101, an investigational vaccine compared to Shingrix for the prevention of herpes zoster in adults aged 50 years and older